UTHR United Therapeutics Corporation

93.13
-1  -1%
Previous Close 94.13
Open 94.48
Price To Book 1.5
Market Cap 4,086,670,126
Shares 43,881,350
Volume 482,282
Short Ratio
Av. Daily Volume 405,099
Stock charts supplied by TradingView

NewsSee all news

  1. United Therapeutics Corporation To Present At The 38th Annual J.P. Morgan Healthcare Conference

    SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Jan. 6, 2020 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ:UTHR) announced today that Martine Rothblatt, Ph.D., Chairman and Chief Executive Officer of

  2. CollPlant Reports Third Quarter 2019 Financial Results and Provides Business Update

    REHOVOT, Israel, Nov. 29, 2019 /PRNewswire/ -- CollPlant (NASDAQ:CLGN), a regenerative medicine company, today announced financial results for the third quarter ended September 30, 2019 and provided an update on the

  3. Correvio Reports Third Quarter 2019 Financial Results

    NASDAQ: CORV  TSX: CORV FDA Accepts Brinavess™ New Drug Application Advisory Committee Date Set for December 10, 2019 PDUFA Date Set for December 24, 2019 Management to Host Conference Call and Webcast Today, November

  4. United Therapeutics Corporation Reports Third Quarter 2019 Financial Results

    SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Oct. 30, 2019 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ:UTHR) today announced its financial results for the quarter ended September 30, 2019. "We are

  5. United Therapeutics Corporation to Report Third Quarter 2019 Financial Results Before the Market Opens on Wednesday, October 30, 2019

    SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Oct. 23, 2019 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ:UTHR) announced today that it will report its third quarter 2019 financial results before the

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 ongoing.
Tyvaso - INCREASE
Pulmonary hypertension associated with idiopathic pulmonary fibrosis (WHO Group 3)
Phase 3 data released April 8, 2019 did not meet primary endpoint.
Esuberaprost - BEAT
Pulmonary arterial hypertension (PAH)
Phase 2/3 planned.
Aurora-GT - (eNOS gene therapy)
Pulmonary arterial hypertension (PAH)
Phase 3 data released August 8, 2018. Primary endpoint met.
Orenitram
Pulmonary arterial hypertension (PAH)
PDUFA date April 27, 2020.
Trevyent
Pulmonary Arterial Hypertension (PAH)
Approved Dec 20 2013
Oral treprostinil
Pulmonary arterial hypertension (PAH)
Phase 3 ongoing. Licensed to UTHR November 15, 2018.
Ralinepag
Pulmonary Arterial Hypertension
Phase 3 portion of trial continues to enroll - noted February 21, 2018.
Unituxin - DISTINCT
Small cell lung cancer

Latest News

  1. United Therapeutics Corporation To Present At The 38th Annual J.P. Morgan Healthcare Conference

    SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Jan. 6, 2020 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ:UTHR) announced today that Martine Rothblatt, Ph.D., Chairman and Chief Executive Officer of

  2. CollPlant Reports Third Quarter 2019 Financial Results and Provides Business Update

    REHOVOT, Israel, Nov. 29, 2019 /PRNewswire/ -- CollPlant (NASDAQ:CLGN), a regenerative medicine company, today announced financial results for the third quarter ended September 30, 2019 and provided an update on the

  3. Correvio Reports Third Quarter 2019 Financial Results

    NASDAQ: CORV  TSX: CORV FDA Accepts Brinavess™ New Drug Application Advisory Committee Date Set for December 10, 2019 PDUFA Date Set for December 24, 2019 Management to Host Conference Call and Webcast Today, November

  4. United Therapeutics Corporation Reports Third Quarter 2019 Financial Results

    SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Oct. 30, 2019 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ:UTHR) today announced its financial results for the quarter ended September 30, 2019. "We are

  5. United Therapeutics Corporation to Report Third Quarter 2019 Financial Results Before the Market Opens on Wednesday, October 30, 2019

    SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Oct. 23, 2019 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ:UTHR) announced today that it will report its third quarter 2019 financial results before the

  6. United Therapeutics Announces FDA Approval Of Updated Label For Orenitram Reflecting Results Of FREEDOM-EV Study

    SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Oct. 21, 2019 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ:UTHR) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplement

  7. Respira Therapeutics Regains North America Rights from United Therapeutics to Phase 2 Inhaled Drug-Device Product, RT234, for Pulmonary Hypertension Indications

    ALBUQUERQUE, N.M., Oct. 10, 2019 /PRNewswire/ -- Respira Therapeutics, a clinical-stage specialty pharmaceutical company developing next-generation cardiopulmonary disease-targeted inhalation products, has regained full

  8. United Therapeutics Announces FDA Acceptance Of Trevyent New Drug Application For Review

    SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Sept. 11, 2019 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ:UTHR) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review